Lara Newman, MD
Cornea and External Diseases Specialist · Greenville, SCNPI 1033557368
Payments from drug & device makers
Across 98 payments — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$703
- Alcon$461
- Dompe US, Inc.$271
- Johnson & Johnson Surgical Vision, Inc.$209
- Astellas Pharma US Inc$207
- Oyster Point Pharma, Inc.$203
- plus $786 from 12 others
What the payments were for
- Food & beverage$2,82199%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $703 |
| Alcon | 15 | $461 |
| Dompe US, Inc. | 5 | $271 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $209 |
| Astellas Pharma US Inc | 4 | $207 |
| Oyster Point Pharma, Inc. | 11 | $203 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $195 |
| Tarsus Pharmaceuticals, Inc. | 6 | $160 |
| Bausch & Lomb Americas Inc. | 6 | $102 |
| Amgen(2 entities) | 4 | $77 |
| Kala Pharmaceuticals, Inc. | 1 | $71 |
| Sun Pharmaceutical Industries Inc. | 3 | $52 |
| Genentech USA, Inc. | 1 | $29 |
| Thea Pharma Inc. | 1 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Harrow Eye, LLC | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Avedro Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$227
- Clareon$134
- VUITY$125
- Tecnis IOL$124
- Izervay$122
- enVista MX60 IOL$107
How this compares
Too few cornea and external diseases specialist providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $362,266 |
| RestasisCyclosporine | 126 | $96,175 |
| XiidraLifitegrast | 49 | $52,671 |
| TyrvayaVarenicline Tartrate | 61 | $51,856 |
| Cyclosporine | 58 | $32,856 |
| Prednisolone Acetate | 471 | $25,772 |
| CequaCyclosporine | 18 | $16,009 |
| ValacyclovirValacyclovir Hcl | 126 | $9,448 |
| Fluorometholone | 86 | $8,025 |
| Difluprednate | 27 | $3,936 |
| Loteprednol Etabonate | 22 | $3,129 |
| Ofloxacin | 198 | $2,827 |
| MoxifloxacinMoxifloxacin Hcl | 85 | $2,797 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $2,133 |
| Doxycycline Hyclate | 75 | $2,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $271 | $362,26613 claims |
| AbbVieRestasis | $703 | $96,175126 claims |
| Bausch & Lomb Americas Inc.Xiidra | $102 | $52,67149 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $203 | $51,85661 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $52 | $16,00918 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $195 | $3,12922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Greenville
- Shawn IversonColumbia$56K
- Jennifer HartelColumbia$4K
- Cameron McGloneCharleston$520
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.